Información de la revista
Compartir
Descargar PDF
Más opciones de artículo
Original article
Disponible online el 15 de julio de 2024
Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk
Efectividad y seguridad de alirocumab y evolocumab para la hipercolesterolemia en una población con alto riesgo cardiovascular
Montserrat Boscha,b,c, Immaculada Danésa,b,c,
, Elena Ballarína,c, Patricia Marrerod, Guillem Vancellsd, Ángel Ortiz-Zúñigae, Maria Urquizu-Padillaf, Nuria Rial-Lorenzof, Jordi Lozano-Torresg, David Rodríguez-Lunah, Francesca Filippi-Arriagaa, Antònia Agustía,b,c
Autor para correspondencia
a Clinical Pharmacology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
b Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain
c Clinical Pharmacology Research Group, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
d Pharmacy Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
e Endocrinology and Nutrition Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
f Internal Medicine Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
g Cardiology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
h Neurology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain